[go: up one dir, main page]

UY31212A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT

Info

Publication number
UY31212A1
UY31212A1 UY31212A UY31212A UY31212A1 UY 31212 A1 UY31212 A1 UY 31212A1 UY 31212 A UY31212 A UY 31212A UY 31212 A UY31212 A UY 31212A UY 31212 A1 UY31212 A1 UY 31212A1
Authority
UY
Uruguay
Prior art keywords
agent
pharmaceutical composition
benzodiazepinic
benzisoxazolic
combination
Prior art date
Application number
UY31212A
Other languages
Spanish (es)
Inventor
Ochoa Victor Guillermo Alvarez
Murillo Josefina Santos
Armenta Maria Elena Garcia
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of UY31212A1 publication Critical patent/UY31212A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención esta relacionada con una composición farmacéutica compuesta por la combinación sinérgica de un agente derivado benzisoxazólico, como lo es el principio activo: Risperidona y un agente benzodiazepínico, como lo es el principio activo: Clonazepam, los cuales se encuentran formulados en una sola unidad de dosificación para ser administrada por vía oral en forma de cápsulas o tabletas, misma que está indicada para el control y tratamiento de enfermedades tales como: trastornos psicóticos y patologías relacionadas.The present invention is related to a pharmaceutical composition composed of the synergistic combination of a benzisoxazole derivative agent, such as the active substance: Risperidone and a benzodiazepineic agent, such as the active substance: Clonazepam, which are formulated in a single Dosing unit to be administered orally in the form of capsules or tablets, which is indicated for the control and treatment of diseases such as: psychotic disorders and related pathologies.

UY31212A 2007-07-06 2008-07-07 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT UY31212A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2007008323A MX2007008323A (en) 2007-07-06 2007-07-06 Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a benzodiazepinic agent.

Publications (1)

Publication Number Publication Date
UY31212A1 true UY31212A1 (en) 2009-01-05

Family

ID=40228771

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31212A UY31212A1 (en) 2007-07-06 2008-07-07 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT

Country Status (4)

Country Link
AR (1) AR067465A1 (en)
MX (1) MX2007008323A (en)
UY (1) UY31212A1 (en)
WO (1) WO2009008695A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10190625B2 (en) 2014-11-18 2019-01-29 Ntn Corporation Thrust roller bearing cage and method for manufacturing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525366A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Also Published As

Publication number Publication date
WO2009008695A1 (en) 2009-01-15
AR067465A1 (en) 2009-10-14
MX2007008323A (en) 2009-02-18

Similar Documents

Publication Publication Date Title
AR093247A1 (en) PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME
MX2009003372A (en) Non-mucoadhesive film dosage forms.
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
BR112013032122A2 (en) modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids
ECSP10010224A (en) LUTEINIZING HORMONE LIQUID FORMULATIONS (LH).
AR091351A1 (en) BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING
BR112014014795A2 (en) immediate release multi-unit pellet system
PE20040973A1 (en) COMPOSITIONS OF ANTI-HISTAMINES, DECONGESTIVES AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
BR112015019776A2 (en) dual-use oral tablets in sulfate salt pharmaceutical compositions and tablet use methods
ECSP099734A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVING AGENT
AR083095A1 (en) APREPITANT L-PROLINA AND PHARMACEUTICAL COMPOSITION CO-CRYSTAL
AR065917A1 (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUBLINGUAL TABLET THAT INCLUDES A NON-STEROID ANTI-INFLAMMATORY AND AN OPIACEAL ANALGESIC FOR PAIN MANAGEMENT
UY31212A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT
UY31363A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN NON-STEROID ANTIFLAMMATORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP, GOTOUS ARTHRITIS AND RELATED DISEASES
UY31230A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTI-CONVULSION AGENT AND A BENZODIAZEPINIC AGENT, INDICATED FOR THE CONTROL AND TREATMENT OF CONVULSIVE DISORDERS AND EPILEPTIC SYNDROMES.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
PE20090316A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS
UY31231A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES.
GT200900275A (en) SYNERGIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN INHIBITOR OF ENZYME 5 A-REDUCTASE AND AN ANTAGONIST OF RECEIVERS 1 A-ANDRENÉRGICOS.
UY31248A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN ANTIANDROGEN AGENT, A SYNTHETIC STERETIC STROGEN AGENT AND VITAMINAL AGENTS, USEFUL FOR THE CONTROL AND TREATMENT OF LATE ACNE IN WOMEN
GT200900316A (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN INHIBITING AGENT OF THE HMG-COA REDUCTASE ENZYME AND AN INHIBITING AGENT OF THE GASTROINTESTINAL ENZYME LIPASE
PE20090725A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTI-ARTHRITIC AGENT AND AN INTERLEUKIN-1 INHIBITING AGENT, USEFUL FOR THE CONTROL AND TREATMENT OF OSTEOARTHROSIS AND RELATED DISEASES
UY31213A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTIDEPRESSIVE AGENT AND AN ANSIOLITIC AGENT FOR THE CONTROL AND TREATMENT OF DEPRESSIVE DISORDERS
ECSP10010012A (en) PHARMACEUTICAL COMPOSITION COMPOSED BY THE COMBINATION OF BETAMETOSONE (STEROID ANTI-INFLAMMATORY AGENT) AND METOCARBAMOL (MUSCLE RELAXING) AND ITS USE IN THE TREATMENT OF MUSCLE SKELETTIC DISEASES
AR071736A1 (en) PHARMACEUTICAL COMPOSITION COMPOSED BY THE COMBINATION OF VARIOUS ANTISPASMODIC AGENTS AND AN NON-STEROID ANTI-INFLAMMATORY AGENT, USEFUL FOR THE CONTROL AND TREATMENT OF RENAL COLICO AND INFLAMMATION

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140924